Clinical trials: Erythropoietin
Anemia
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
The primary purpose of this study is to determine the effect of Epoetin Alfa (Procrit) on the change in hemoglobin (red blood cell count) in anemic kidney transplant recipients.
- Trial name
- NCT01290328
- Testing
- Epoetin Alfa
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mehrotra, Anita, M.D.
Non-Small-Cell Lung Carcinoma, Lung Cancer
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
The general objective of this study is to improve the Quality of Life (QoL) of selected patients with advanced carcinoma of the lung.
- Conditions
- Non-Small-Cell Lung Carcinoma, Lung Cancer, Anemia
- Trial name
- NCT00310232
- Testing
- Epoetin Alfa
- Where
- 15 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Cancer, Non-Myeloid Malignancies
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
The purpose of this study is to compare the time to hematopoietic response (hemoglobin correction to 12 g/dL or a greater than or equal to 2 g/dL increase from baseline) for subjects randomized to receive darbepoetin alfa with a…
- Trial name
- NCT00111137
- Testing
- rHuEPO, Darbepoetin alfa
- Volunteers
- 718 people
- Sponsor
- Amgen
Anaemia
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease
This study aims to characterize the relationship between dose of GSK1278863 and hemoglobin (Hgb) response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD).
- Trial name
- NCT02019719
- Testing
- GSK1278863
- Where
- 21 sites in Japan
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Contrast Induced Nephropathy
Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial
Full Title: A Randomized Controlled Trial of Procrit for the Prevention of Acute Renal Failure in Patients Receiving Intravenous Contrast Primary Objective: To evaluate the efficacy of a one-time dose of intravenous…
- Trial name
- ERIN (NCT00476619)
- Testing
- erythropoeitin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Brigham and Women's Hospital
Leukemia
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
The goal of this clinical research study is to learn if Procrit (epoetin alfa) will decrease the need for blood transfusions in patients with Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma (LL), or Burkitt's who are…
- Trial name
- NCT01099202
- Testing
- Procrit (epoetin alfa)
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- M.D. Anderson Cancer Center
Anemia
Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy
The purpose of this study is to evaluate the safety and efficacy of PROCRIT (Epoetin alfa) when administered at 120,000 Units once every three weeks by comparing early dosing (Hb 11g/dL-12g/dL) vs. standard dosing (Hb< 11g/dL).
- Trial name
- NCT00210600
- Testing
- PROCRIT (Epoetin alfa)
- Volunteers
- 186 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Azacitidine has proved prolonged overall survival in patients with high-risk MDS. Minor pilot studies have shown that treatment with Azacitidine can induce transfusion independency in previous transfusion dependent patients with…
- Trial name
- NCT01048034
- Testing
- Azacitidine, Erythropoetin
- Where
- 17 sites in Denmark, Norway and 1 more
- Volunteers
- 30 people
- Sponsor
- Nordic MDS Group
Hip Fractures
Efficacy of Ferric Carboxymaltose With or Without EPO Reducing Red-cell Transfusion Packs in Hip Fracture Perioperative Period
In order to evaluate the efficacy of ferric carboxymaltose + erythropoietin versus ferric carboxymaltose versus placebo in reducing the percentage of patients who receive red-cell transfusion in the perioperative period of hip…
- Trial name
- PAHFRAC (NCT01154491)
- Testing
- Ferric carboxymaltose, Erythropoietin
- Where
- 14 sites in Spain
- Volunteers
- 303 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
HIV Infections, Cytopenias
Treatment Program for Anemia in AIDS Patients
The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.
- Trial name
- NCT00002022
- Testing
- Epoetin alfa
- Where
- United States
- Sponsor
- R W Johnson Pharmaceutical Research Institute
Hepatitis C
Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection
The purpose of this study is to determine if the use of epoetin-alpha will allow patients with chronic hepatitis C virus infection to be treated with higher doses of peginterferon-alpha-2b and ribavirin, thus increasing chances…
- Trial name
- NCT00248339
- Testing
- Peginterferon-alpha-2b (PEG-Intron), Ribavirin, Epoetin-alpha (Procrit)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Virginia Commonwealth University
Anemia
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy.
- Trial name
- NCT00354341
- Testing
- Epoetin beta
- Where
- 63 sites in Austria, Brazil and 15 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Traumatic Brain Injury
Erythropoietin in Traumatic Brain Injury (EPO-TBI)
This study seeks to determine if erythropoietin alpha (EPO) administered to adult critical care patients with moderate or severe traumatic brain injury improves neurological function assessed at six months after injury.
- Trial name
- EPO-TBI (NCT00987454)
- Testing
- Epoetin Alfa, Sodium Chloride 0.9%
- Where
- 28 sites in Australia, Finland and 5 more
- Volunteers
- 606 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Neonatal Hypoxic Ischemic Encephalopathy
Erythropoietin in HIE Neonate
this study is aim to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy the study is conducted to answer the question : is erythropoietin will improve neonatal hypoxic ischemic…
- Trial name
- NCT06590155
- Testing
- Erythropoietin
- Where
- Egypt
- Volunteers
- 3 people
- Sponsor
- Assiut University
CKD Anemia in Stable Dialysis Patients
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
- Trial name
- NCT02273726
- Testing
- Epoetin Alfa, Roxadustat
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 741 people
- Sponsor
- Kyntra Bio
Diabetic Nephropathy, Anemia
Roxadustat Versus Erythropoietin for Anaemia Treatment in Diabetic Nephropathy
This randomized controlled trial compared roxadustat with erythropoietin for the treatment of anaemia in patients with diabetic nephropathy and chronic kidney disease.
- Conditions
- Diabetic Nephropathy, Anemia, Chronic Kidney Disease
- Trial name
- NCT07786168
- Testing
- Roxadustat, Erythropoietin
- Where
- Pakistan
- Volunteers
- 64 people
- Sponsor
- Hanzla Arshad
Anaemia Associated With Chronic Kidney Disease
A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
This is an open-label, randomised, multicenter, Mircera-controlled, parallel-group, Phase III study to determine whether subcutaneous administered efepoetin alfa is as effective and well tolerated as subcutaneous Mircera for…
- Trial name
- NCT04155125
- Testing
- efepoetin alfa, Mircera
- Where
- 55 sites in Australia, Indonesia and 5 more
- Volunteers
- 391 people
- Sponsor
- PT Kalbe Genexine Biologics
Chronic Kidney Disease, End-Stage Renal Failure
Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia
The purpose of this study is to establish the long-term safety and efficacy of Biogeneric Epoetin, the attainability of therapeutic target for anaemia management, and the impact of Epoetin treatment on long-term health outcome…
- Conditions
- Chronic Kidney Disease, End-Stage Renal Failure, Anaemia
- Trial name
- NCT00238043
- Testing
- Biogeneric Epoetin
- Where
- 14 sites in Malaysia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Malaysia
Anemia
A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia
This 2 arm study will compare the efficacy and safety of monthly administration of intravenous (IV) Mircera versus epoetin alfa for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia.
- Trial name
- NCT00605293
- Testing
- methoxy polyethylene glycol-epoetin beta, Epoetin alfa
- Where
- 19 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Hoffmann-La Roche
Anemia, Breast Neoplasms
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
The purpose of this study is to evaluate the impact on survival and quality of life of maintaining hemoglobin in the range of 12 to 14 g/dL using epoetin alfa or placebo in patients starting chemotherapy for metastatic breast…
- Conditions
- Anemia, Breast Neoplasms, Quality of Life
- Trial name
- NCT00211133
- Testing
- epoetin alfa
- Volunteers
- 939 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.